keyword
MENU ▼
Read by QxMD icon Read
search

Vaccine adverse events

keyword
https://www.readbyqxmd.com/read/28819380/phase-ii-trial-of-adjuvant-immunotherapy-with-autologous-tumor-derived-gp96-vaccination-in-patients-with-gastric-cancer
#1
Kecheng Zhang, Zheng Peng, Xiaohui Huang, Zhi Qiao, Xinxin Wang, Ning Wang, Hongqing Xi, Jianxin Cui, Yunhe Gao, Xijian Huang, Hua Gao, Bo Wei, Lin Chen
Background/Aims: Autologous, tumor-derived, heat shock protein gp96 peptide complexes have antitumor potential. We conducted the first Phase II trial to evaluate the safety and efficacy of gp96 vaccination in adjuvant settings for patients with gastric cancer. Methods: We enrolled 73 consecutive patients from October 2012 to December 2015. Thirty-eight patients received gp96 vaccination plus chemotherapy and 35 received chemotherapy alone. The primary endpoints were disease-free survival (DFS) and toxicity...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28812030/safety-of-human-papillomavirus-9-valent-vaccine-a-meta-analysis-of-randomized-trials
#2
REVIEW
Ana Paula Ferreira Costa, Ricardo Ney Oliveira Cobucci, Janine Medeiros da Silva, Paulo Henrique da Costa Lima, Paulo César Giraldo, Ana Katherine Gonçalves
Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28811965/adjuvant-immunotherapy-with-autologous-dendritic-cells-for-hepatocellular-carcinoma-randomized-phase-ii-study
#3
Jeong-Hoon Lee, Won Young Tak, Yoon Lee, Min-Kyu Heo, Jae-Sung Song, Hak-Yeop Kim, Soo Young Park, Si Hyun Bae, Joon Hyeok Lee, Jeong Heo, Ki-Hwan Kim, Yong-Soo Bae, Yoon Jun Kim
Our previous phase I/IIA study showed that autologous dendritic cells (DCs) pulsed with tumor-associated antigens are well tolerated in patients with hepatocellular carcinoma (HCC). In this randomized, multicenter, open-label, phase II trial, we investigated the efficacy and safety of this DC-based adjuvant immunotherapy with 156 patients, who treated for HCC with no evidence of residual tumor after standard treatment modalities. Patients were randomly assigned to immunotherapy (n = 77; injection of 3 × 10(7) DC cells, six times over 14 weeks) or control (n = 79; no treatment)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28803715/a-phase-1-randomized-open-label-clinical-study-to-evaluate-the-safety-and-tolerability-of-a-novel-recombinant-hepatitis-e-vaccine
#4
Yu-Feng Cao, Hong Tao, Yue-Mei Hu, Cheng-Bo Shi, Xing Wu, Qi Liang, Chun-Ping Chi, Li Li, Zheng-Lun Liang, Ji-Hong Meng, Feng-Cai Zhu, Zhao-Hui Liu, Xin-Ping Wang
BACKGROUND: This study aimed to evaluate the safety and tolerability for variable dosages of a novel hepatitis E vaccine p179. METHODS: The randomized open-label parallel control phase 1 clinical trial enrolled 120 eligible participants aged 16-65years in Jiangsu Province, China. The experimental groups were randomized to receive different dosages of 20μg, 30μg, and 40μg Hepatitis E Virus (HEV) p179 vaccines, with the 30μgHEV vaccine p239 Hecolin as control, and vaccinated at 0, 1 and 6month intervals...
August 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28803714/building-capacity-for-active-surveillance-of-vaccine-adverse-events-in-the-americas-a-hospital-based-multi-country-network
#5
Pamela Bravo-Alcántara, Silvia Pérez-Vilar, Helvert Felipe Molina-León, Miriam Sturkenboom, Steven Black, Patrick L F Zuber, Christine Maure, Jose Luis Castro
New vaccines designed to prevent diseases endemic in low and middle-income countries are being introduced without prior utilization in countries with robust vaccine pharmacovigilance systems. Our aim was to build capacity for active surveillance of vaccine adverse events in the Americas. We describe the implementation of a proof-of-concept study for the feasibility of an international collaborative hospital-based active surveillance system for vaccine safety. The study was developed and implemented in 15 sentinel sites located in seven countries of the region of the Americas, under the umbrella of the World Health Organization (WHO) Global Vaccine Safety Initiative...
August 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28803712/oral-cholera-vaccine-coverage-in-hard-to-reach-fishermen-communities-after-two-mass-campaigns-malawi-2016
#6
Delphine Sauvageot, Christel Saussier, Abebe Gobeze, Sikhona Chipeta, Innocent Mhango, Gift Kawalazira, Martin A Mengel, Dominique Legros, Philippe Cavailler, Maurice M'bang'ombe
CONTEXT: From December 2015 to August 2016, a large epidemic of cholera affected the fishermen of Lake Chilwa in Malawi. A first reactive Oral Cholera Vaccines (OCV) campaign was organized, in February, in a 2km radius of the lake followed by a preemptive one, conducted in November, in a 25km radius. We present the vaccine coverage reached in hard-to-reach population using simplified delivery strategies. METHOD: We conducted two-stage random-sampling cross-sectional surveys among individuals living in a 2km and 25km radius of Lake Chilwa (islands and floating homes included)...
August 10, 2017: Vaccine
https://www.readbyqxmd.com/read/28801947/how-will-transitioning-from-cytology-to-hpv-testing-change-the-balance-between-the-benefits-and-harms-of-cervical-cancer-screening-estimates-of-the-impact-on-cervical-cancer-treatment-rates-and-adverse-obstetric-outcomes-in-australia-a-high-vaccination-coverage
#7
Louiza S Velentzis, Michael Caruana, Kate T Simms, Jie-Bin Lew, Ju-Fang Shi, Marion Saville, Megan A Smith, Sarah J Lord, Jeffrey Tan, Deborah Bateson, Michael Quinn, Karen Canfell
Primary HPV screening enables earlier diagnosis of cervical lesions compared to cytology, however, its effect on the risk of treatment has not been investigated. We estimated the cumulative lifetime risk (CLR) of cervical cancer and excisional treatment; and change in adverse obstetric outcomes in HPV unvaccinated women and cohorts offered vaccination (>70% coverage in 12-13 years) for the Australian cervical screening program. 2-yearly cytology screening (ages 18-69 years) was compared to 5-yearly primary HPV screening with partial genotyping for HPV16/18 (ages 25-74 years)...
August 12, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28796684/maternal-and-infant-outcomes-after-human-papillomavirus-vaccination-in-the-periconceptional-period-or-during-pregnancy
#8
Heather S Lipkind, Gabriela Vazquez-Benitez, James D Nordin, Paul A Romitti, Allison L Naleway, Nicola P Klein, Rulin C Hechter, Michael L Jackson, Simon J Hambidge, Grace M Lee, Lakshmi Sukumaran, Elyse O Kharbanda
OBJECTIVE: To evaluate whether quadrivalent human papillomavirus (HPV) vaccine administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects. METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. Insured women 13-27 years old with singleton pregnancies and a live birth from January 1, 2007, through September 1, 2013, who received quadrivalent HPV vaccine during the periconceptional period (2 weeks before to 2 weeks after their last menstrual period), during pregnancy, or during both periods combined were compared with women who had a live birth during the same time period and received quadrivalent HPV vaccine 4-18 months before their last menstrual period...
August 4, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28794096/an-increase-in-accident-and-emergency-presentations-for-adverse-events-following-immunisation-after-introduction-of-the-group-b-meningococcal-vaccine-an-observational-study
#9
Viveka Nainani, Ushma Galal, Jim Buttery, Matthew D Snape
OBJECTIVES: To determine whether the introduction of the capsular group B meningococcal vaccine (4CMenB) in the UK has increased presentations of infants to emergency departments with adverse events following immunisation (AEFI). PARTICIPANTS, DESIGN AND SETTING: A retrospective review of hospital records of infants aged 1-6 months presenting to Oxford University Hospitals NHS Trust's emergency departments from September 2013 to August 2016 with discharge diagnoses of vaccine reactions or non-specific conditions...
August 9, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28789851/antibody-persistence-and-evidence-of-immune-memory-at-5years-following-administration-of-the-9-valent-hpv-vaccine
#10
Ana Guevara, Robinson Cabello, Linn Woelber, Edson Duarte Moreira, Elmar Joura, Olaf Reich, Christine Shields, Misoo C Ellison, Amita Joshi, Alain Luxembourg
BACKGROUND: The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characterized by the generation of immune memory...
August 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28777109/influenza-immunization-of-pregnant-women-in-resource-constrained-countries-an-update-for-funding-and-implementation-decisions
#11
Justin R Ortiz, Kathleen M Neuzil
PURPOSE OF REVIEW: In 2018, Gavi, the Vaccine Alliance, is expected to review the strategy of maternal influenza immunization for potential investment in low-income countries. RECENT FINDINGS: Clinical trial data confirm the efficacy of maternal influenza immunization to prevent influenza disease in both mothers and their infants during the first months of life. Trial and observational data indicate no significant adverse events in mothers or newborns. High-quality disease burden data, particularly for seasonal influenza in low-income and middle-income countries, are limited...
August 4, 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/28774563/adverse-events-following-live-attenuated-intranasal-influenza-vaccination-of-children-with-cystic-fibrosis-results-from-two-influenza-seasons
#12
Constantina Boikos, Lawrence Joseph, David Scheifele, Larry C Lands, Gaston De Serres, Jesse Papenburg, Nicholas Winters, Mark Chilvers, Caroline Quach
BACKGROUND: Despite the approved use of live-attenuated intranasal influenza vaccine (LAIV) for seasonal immunization of patients with cystic fibrosis (CF), many questions remain unanswered regarding the timing, duration, and types of adverse events that occur following administration of this vaccine. METHODS: In 2012 and 2013, 264 LAIV doses were administered to 198 patients aged 2-19 with CF. Vaccinees were followed prospectively for 55 days after vaccination (day 0) and information on adverse events was collected...
July 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28774561/personalized-vaccinology-a-review
#13
G A Poland, I G Ovsyannikova, R B Kennedy
At the current time, the field of vaccinology remains empirical in many respects. Vaccine development, vaccine immunogenicity, and vaccine efficacy have, for the most part, historically been driven by an empiric "isolate-inactivate-inject" paradigm. In turn, a population-level public health paradigm of "the same dose for everyone for every disease" model has been the normative thinking in regard to prevention of vaccine-preventable infectious diseases. In addition, up until recently, no vaccines had been designed specifically to overcome the immunosenescence of aging, consistent with a post-WWII mentality of developing vaccines and vaccine programs for children...
July 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28770638/systematic-literature-review-comparing-rapid-3-dose-administration-of-the-gsk-tick-borne-encephalitis-vaccine-with-other-primary-immunization-schedules
#14
Ilaria Galgani, Eveline M Bunge, Lisa Hendriks, Christopher Schludermann, Cinzia Marano, Laurence De Moerlooze
Tick-borne encephalitis (TBE), which is endemic across large regions of Europe and Asia, is most effectively prevented through vaccination. Three-dose primary TBE vaccination schedules are either rapid (0,7,21-days) or conventional (0,28-84-days, 9-12-months). The second dose can also be administered at 14 days for faster priming and sero-protection). Areas covered: We used a three-step selection process to identify 21 publications comparing the immunogenicity and/or safety of different schedules. Expert commentary: Priming with two or three TBE vaccine doses was highly immunogenic...
September 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28763922/-analysis-on-death-from-adverse-event-following-immunization-surveillance-system-of-shandong-province-during-2011-2016
#15
Y J Zhang
Objective: To analyze the occurrence and death of Adverse Event Following Immunization (AEFI) in Shandong province. Methods: Collecting the information of AEFI cases from 2011 to 2016, which were reported through the National AEFI Management System in Shandong province up to January 15, 2017. The autopsy reports of death following immunization were issued by the qualified institutions. The inoculation data from 2011 to 2016 was obtained through Immunization Information Management System of Shandong province...
August 6, 2017: Zhonghua Yu Fang Yi Xue za Zhi [Chinese Journal of Preventive Medicine]
https://www.readbyqxmd.com/read/28762675/major-birth-defects-after-vaccination-reported-to-the-vaccine-adverse-event-reporting-system-vaers-1990-to-2014
#16
Pedro L Moro, Janet Cragan, Paige Lewis, Lakshmi Sukumaran
BACKGROUND: Major birth defects are important infant outcomes that have not been well studied in the postmarketing surveillance of vaccines given to pregnant women. We assessed the presence of major birth defects following vaccination in the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system used to monitor the safety of vaccines in the United States. METHODS: We searched VAERS for reports of major birth defects during January 1, 1990, through December 31, 2014...
July 17, 2017: Birth defects research
https://www.readbyqxmd.com/read/28761614/-impact-of-controlled-temperature-chain-ctc-approach-on-immunization-coverage-achieved-during-the-preventive-vaccination-campaign-against-meningitis-a-using-menafrivac-in-togo-in-2014
#17
Dadja Essoya Landoh, Anna-Léa Kahn, Anani Lacle, Kodjovi Adjeoda, Bayaki Saka, Issifou Yaya, Danladi Ibrahim Nassoury, Assima Kalao, Makawa-Sy Makawa, Nsiari-Mueyi Joseph Biey, Andre Bita, Yaovi Temfa Toke, Petit Dörte, Lucile Imboua, Olivier Ronveaux
METHOD: We conducted a survey from 9 to 14 March 2015 (for approximately 3 months) after the end of the vaccination campaign in these four regions. Interviewees were selected using two stages cluster sampling stratified according to the regions. MenAfriVac vaccine in Controlled Temperature Chain (CTC) was used in 10 districts, in Togo. RESULTS: A total of 2707 households were surveyed and 9082 people aged 1-29 years were interviewed. The average age of the individuals surveyed was 11...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28755028/erratum-to-serious-adverse-events-after-hpv-vaccination-a-critical-review-of-randomized-trials-and-post-marketing-case-series
#18
Manuel Martínez-Lavín, Luis Amezcua-Guerra
No abstract text is available yet for this article.
July 29, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28754494/safety-and-immunogenicity-of-a-mrna-rabies-vaccine-in-healthy-adults-an-open-label-non-randomised-prospective-first-in-human-phase-1-clinical-trial
#19
Martin Alberer, Ulrike Gnad-Vogt, Henoch Sangjoon Hong, Keyvan Tadjalli Mehr, Linus Backert, Greg Finak, Raphael Gottardo, Mihai Alexandru Bica, Aurelio Garofano, Sven Dominik Koch, Mariola Fotin-Mleczek, Ingmar Hoerr, Ralf Clemens, Frank von Sonnenburg
BACKGROUND: Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV7201). METHODS: We did an open-label, uncontrolled, prospective, phase 1 clinical trial at one centre in Munich, Germany. Healthy male and female volunteers (aged 18-40 years) with no history of rabies vaccination were sequentially enrolled...
July 25, 2017: Lancet
https://www.readbyqxmd.com/read/28750854/tularemia-vaccine-safety-reactogenicity-take-skin-reactions-and-antibody-responses-following-vaccination-with-a-new-lot-of-the-francisella-tularensis-live-vaccine-strain-a-phase-2-randomized-clinical-trial
#20
Mark J Mulligan, Jack T Stapleton, Wendy A Keitel, Sharon E Frey, Wilbur H Chen, Nadine Rouphael, Srilatha Edupuganti, Allison Beck, Patricia L Winokur, Hana M El Sahly, Shital M Patel, Robert L Atmar, Irene Graham, Edwin Anderson, Samer S El-Kamary, Marcela F Pasetti, Marcelo B Sztein, Heather Hill, Johannes B Goll
BACKGROUND: Tularemia is caused by Francisella tularensis, a gram-negative bacterium that has been weaponized as an aerosol. For protection of personnel conducting biodefense research, the United States Army required clinical evaluation of a new lot of tularemia live vaccine strain manufactured in accordance with Current Good Manufacturing Practices. METHODS: A phase 2 randomized clinical trial compared the new lot (DVC-LVS) to the existing vaccine that has been in use for decades (USAMRIID-LVS)...
July 24, 2017: Vaccine
keyword
keyword
15634
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"